Pharma Deals Review, Vol 2004, No 49 (2004)

Font Size:  Small  Medium  Large

Abbott Acquires Remaining Rights to Trandolapril from Aventis

Business Review Editor

Abstract


Abbott Laboratories acquired the remaining manufacturing and marketing rights to trandolapril and its combination drug verapamil from Aventis for a total payment of US$300 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.